CVEvulnerability

CVE-2025-61940

8.7 HIGH Published 2025-12-02 Modified 2026-09-25 Official page ↗
Status
Analyzed
Published
2025-12-02
Last modified
2026-09-25
Assigner
[email protected]
CVSS 4.0 ([email protected])
8.7 HIGH — CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
CVSS 3.1 ([email protected])
8.3 HIGH — CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L
CVSS 3.1 ([email protected])
8.8 HIGH — CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
Weaknesses
CWE-603

Description

NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.

Affected configurations

• mirion biodose\/nmis (< 23.0)

Related

Weakness · CWE (1)

  • CWE-603 Use of Client-Side Authentication weakness

References